{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/asthma/prescribing-information/leukotriene-receptor-antagonists/","result":{"pageContext":{"chapter":{"id":"d8174f33-d787-5076-88b5-f4c67df93128","slug":"leukotriene-receptor-antagonists","fullItemName":"Leukotriene receptor antagonists","depth":2,"htmlHeader":"<!-- begin field 6af39be8-c628-4a9b-ba85-a6d7016ba4be --><h2>Leukotriene receptor antagonists </h2><!-- end field 6af39be8-c628-4a9b-ba85-a6d7016ba4be -->","summary":"","htmlStringContent":"<!-- begin item 2626bec7-75d5-4caa-9158-a6d7016b9de8 --><!-- end item 2626bec7-75d5-4caa-9158-a6d7016b9de8 -->","topic":{"id":"d631356f-d3a3-51fb-807c-5517c470a5af","topicId":"2a0a90e6-1c4e-4b6a-9ce2-3379dd122594","topicName":"Asthma","slug":"asthma","lastRevised":"Last revised in October 2020","chapters":[{"id":"c7185669-75fd-5c6e-b105-63a3237634ac","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"9fe1ab10-4b4d-5ba8-9ef0-00631cd00ea4","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"770d55df-2c61-5d1e-83d9-92b12ccae96a","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"d2031db2-44fd-55bb-b5c8-d085b387747a","slug":"changes","fullItemName":"Changes"},{"id":"a993bde1-1ac8-529e-8a3e-201a8c082ab2","slug":"update","fullItemName":"Update"}]},{"id":"eae8fe92-3941-512e-bcc6-f1e15157c1ae","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"8e125759-cd9d-510d-9659-3c2e77baa755","slug":"goals","fullItemName":"Goals"},{"id":"a6c91cd5-1ce2-5c60-86cc-341a9dccf3d4","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"a5746054-2f36-5a42-9e7c-7af9107ad99b","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"5fd19cd9-6ac7-54c8-89be-817d58e41309","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"f7339086-c653-53dd-990c-6d470fa223b8","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"f43b79db-3c62-58ee-bb70-932e6613eea6","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"0d12a387-5436-5c75-92c0-189cb391ec7a","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"8fbe04ed-5fd7-54c9-be84-6c959f75af3b","slug":"definition","fullItemName":"Definition"},{"id":"5cbe6206-f80c-5a71-8e4d-a4d44e392874","slug":"prevalence","fullItemName":"Prevalence"},{"id":"2fb588ab-6181-5aec-8a4a-fb368098329d","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"b786654f-5e6e-5e5f-9ead-abaca7f99ba5","slug":"prognosis","fullItemName":"Prognosis"},{"id":"c0b65c0b-957e-538e-83e9-5b4af2d8e6dd","slug":"complications","fullItemName":"Complications"}]},{"id":"574c6193-f36f-5bf7-946a-d8c688476131","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"351773e5-286c-5560-8402-79c2d92d4aa6","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"053272da-fea9-5df6-842a-0de682896aaf","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"7b632c20-012f-590e-a01e-cda5715d6f14","fullItemName":"Management","slug":"management","subChapters":[{"id":"f95fb73f-b749-53a5-b857-4d2bb9945667","slug":"newly-diagnosed-asthma","fullItemName":"Scenario: Newly-diagnosed asthma"},{"id":"2878c5f8-3e3f-52c8-a9bd-7988906b6f99","slug":"follow-up","fullItemName":"Scenario: Follow-up"},{"id":"2458c073-8efb-5a81-8bc4-9a543deab17d","slug":"acute-exacerbation-of-asthma","fullItemName":"Scenario: Acute exacerbation of asthma"},{"id":"45a1b06c-1e5d-56b4-8da7-a8abf4f6c7cc","slug":"covid-19","fullItemName":"Scenario: COVID-19"}]},{"id":"fb9dc424-4306-54a1-b06b-1b01273ac473","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"52940123-8084-55c3-b593-cc9fe50daf8f","slug":"azithromycin","fullItemName":"Azithromycin"},{"id":"5eb1288c-29af-59c1-b623-bd0010732835","slug":"beta-2-agonists","fullItemName":"Beta-2 agonists"},{"id":"dc8f7545-ff7a-5bf1-8ac8-95161137fac5","slug":"inhaled-corticosteroids","fullItemName":"Inhaled corticosteroids"},{"id":"4d715496-c821-52e3-8ea0-d05cfb33d3eb","slug":"oral-corticosteroids","fullItemName":"Oral corticosteroids"},{"id":"d8174f33-d787-5076-88b5-f4c67df93128","slug":"leukotriene-receptor-antagonists","fullItemName":"Leukotriene receptor antagonists"},{"id":"a556cd4f-1851-52fd-a993-34e977a27fd2","slug":"muscarinic-agents","fullItemName":"Muscarinic agents"},{"id":"0cea3b69-b77b-505e-bded-6fceaca145df","slug":"theophylline","fullItemName":"Theophylline"},{"id":"550429f1-7cab-5f16-b476-e479d8084c03","slug":"cromones","fullItemName":"Cromones"}]},{"id":"76b3dfce-ba54-5456-a259-79b345a5e064","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"e31b3681-17cc-5ff2-ba28-d3b1fcb0a82c","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"2bcf3eeb-fd2e-5d40-a52f-da626afbbe01","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"14ea4312-4846-5381-a82c-dc6b03a60d04","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"e4987bc8-0a78-59eb-bfda-f9de7c9ee182","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"be4f3045-8192-53b7-81a3-b460bb2218bc","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"82ae443c-942c-5053-a988-38bce8dec570","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"efdf3cf8-dee5-5351-9d2d-346b4fdf9faf","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"fb9dc424-4306-54a1-b06b-1b01273ac473","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"83ba51e7-a6ef-54a6-bb55-25d0f3ce6795","slug":"dose","fullItemName":"Dose","depth":3,"htmlHeader":"<!-- begin field 43415854-9c8d-4e86-8774-a6f700ee84ab --><h3>Which dose should be given?</h3><!-- end field 43415854-9c8d-4e86-8774-a6f700ee84ab -->","summary":"","htmlStringContent":"<!-- begin item 9882fc1f-1f03-47cf-b33d-a6f700ee82cd --><!-- begin field f2730f2c-fc9b-4a2f-bc7f-a6f700ee84ab --><p><strong>Montelukast and zafirlukast are leukotriene receptor antagonists taken orally in the treatment of asthma. Doses are as follows:</strong></p><ul><li><strong>Montelukast</strong> — 10 mg once daily in adults and children aged 15 years and older, 5 mg once daily in children aged 6–14 years, and 4 mg once daily in children aged 6 months to 5 years. Doses to be taken in the evening.</li><li><strong>Zafirlukast</strong> — 20 mg twice daily in adults and children aged 12 years and older. Not licensed for use in younger children.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/asthma/references/\">BNF 75, 2018</a>] </p><!-- end field f2730f2c-fc9b-4a2f-bc7f-a6f700ee84ab --><!-- end item 9882fc1f-1f03-47cf-b33d-a6f700ee82cd -->","subChapters":[]},{"id":"0fb7ce2f-eb2e-53c0-94a8-c31f0db5080c","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field b211a1ee-1b42-4fb8-833d-a6da00fba44d --><h3>Contraindications and cautions</h3><!-- end field b211a1ee-1b42-4fb8-833d-a6da00fba44d -->","summary":"","htmlStringContent":"<!-- begin item 694198d3-855f-458d-8ff8-a6da00fba1c8 --><!-- begin field 5c3a7fef-0b0b-4f73-8d7f-a6da00fba44d --><ul><li>There are no noted contraindications or cautions for montelukast.</li><li>Zafirlukast is contraindicated in people with hepatic impairment or cirrhosis.</li><li>The use of Zafirlukast in children under 12 years is contraindicated until safety information becomes available. </li><li>Zafirlukast should be used with caution in people with mild to severe renal impairment. Experience of use in these groups is limited, and clear dose recommendations can therefore not be given.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/asthma/references/\">ABPI, 2016b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/asthma/references/\">ABPI, 2018a</a>]</p><!-- end field 5c3a7fef-0b0b-4f73-8d7f-a6da00fba44d --><!-- end item 694198d3-855f-458d-8ff8-a6da00fba1c8 -->","subChapters":[]},{"id":"b98311a8-253e-5dcd-b6eb-5ed0cd29b911","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field a9c279f3-9001-4fc6-a85c-a6da00fbd4ae --><h3>Adverse effects</h3><!-- end field a9c279f3-9001-4fc6-a85c-a6da00fbd4ae -->","summary":"","htmlStringContent":"<!-- begin item 71556ea0-c4d4-488a-87c3-a6da00fbd25c --><!-- begin field 068be596-c6e1-4a90-890b-a6da00fbd4ae --><ul><li><strong>Adverse effects of montelukast include:</strong><ul><li>Arthralgia.</li><li>Bruising.</li><li>Dyspepsia.</li><li>Excessive thirst.</li><li>Gastrointestinal upset.</li><li>Headache.</li><li>Hyperkinesia (in young children).</li><li>Infections.</li><li>Malaise.</li><li>Myalgia.</li><li>Nose bleeds.</li><li>Nervous system disorders (dizziness, drowsiness, paraesthesia/hypoesthesia, seizure).</li><li>Oedema.</li><li>Psychiatric disorders (dream abnormalities including nightmares, insomnia, somnambulism, anxiety, agitation including aggressive behaviour or hostility, depression, psychomotor hyperactivity [including irritability, restlessness and tremor]). </li><li>Rash.</li><li>Thrombocytopaenia.</li><li>Tic.</li><li>Enuresis in children.</li></ul></li><li><strong>Adverse effects of zafirlukast include:</strong><ul><li>Arthralgia.</li><li>Bruising.</li><li>Gastrointestinal upset.</li><li>Headache.</li><li>Hepatic disorder.<ul><li>The person or their parent/carer should be advised to be alert for signs and symptoms of hepatic disorder (persistent nausea, vomiting, malaise, or jaundice) and to seek medical attention if they develop.</li></ul></li><li>Hyperbilirubinemia.</li><li>Infections.</li><li>Insomnia.</li><li>Malaise.</li><li>Muscle cramps.</li><li>Myalgia.</li><li>Rash.</li></ul></li><li><strong>Very rarely, leukotriene receptor antagonists have been associated with systemic eosinophilia, eosinophilic pneumonia, or with clinical features of systemic vasculitis, consistent with Churg-Strauss syndrome.</strong><ul><li>If a person develops an eosinophilic condition, or a Churg-Strauss syndrome-type illness, the leukotriene receptor antagonist should be stopped.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/asthma/references/\">ABPI, 2016b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/asthma/references/\">ABPI, 2018a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/asthma/references/\">BNF 75, 2018</a>]</p><!-- end field 068be596-c6e1-4a90-890b-a6da00fbd4ae --><!-- end item 71556ea0-c4d4-488a-87c3-a6da00fbd25c -->","subChapters":[]},{"id":"1008673a-1e25-5169-9a73-c378cd036cc3","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field efd42eb5-fc2b-4ea5-a798-a6da00fbba64 --><h3>Drug interactions</h3><!-- end field efd42eb5-fc2b-4ea5-a798-a6da00fbba64 -->","summary":"","htmlStringContent":"<!-- begin item 56ba43d7-0d5e-418e-9118-a6da00fbb7dd --><!-- begin field 8fd32c1f-45fc-44ac-bf44-a6da00fbba64 --><ul><li><strong>Phenytoin, phenobarbital and rifampicin</strong> — These are inducers of CYP 3A4, 2C8 and 2C9 which also metabolise montelukast. Caution should be exercised, particularly in children as plasma levels of montelukast may be reduced with co-administration.</li><li><strong>Aspirin</strong> — Co-administration of zafirlukast and aspirin 650 mg four times a day may result in approximately 45% increased zafirlukast levels.</li><li><strong>Warfarin </strong>— Zafirlukast co-administration results in an approximately 35% increase in maximum prothrombin time. Prothrombin time should therefore be closely monitored in people receiving both drugs.</li><li><strong>Theophylline</strong> — Zafirlukast co-administered with theophylline has been observed rarely to result in increased theophylline levels. Theophylline levels should therefore be monitored in people receiving both drugs.</li><li><strong>Erythromycin</strong> — Zafirlukast co-administered with erythromycin results in 40% decreased plasma level of zafirlukast. </li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/asthma/references/\">ABPI, 2016b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/asthma/references/\">ABPI, 2018a</a>]</p><!-- end field 8fd32c1f-45fc-44ac-bf44-a6da00fbba64 --><!-- end item 56ba43d7-0d5e-418e-9118-a6da00fbb7dd -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}